FDA publishes Draft on Medical Devices Recalls Guideline
The FDA has published an independent industry guideline on product recalls, biological and medical devices ("Product Recalls, Including Removals and Corrections"). According to this guideline, the FDA requires very detailed information in cases of recalls (What type of defect? Is there some potential health hazard?, etc.). The guideline describes deficiencies which refer to regulations like for example the GMPs.
Sometimes, there are reasons for a certain "type of recall" which isn't due to a product deficiency. For example, a product currently on the market may be replaced by a newer, better one. In this case, the reason for the "recall" is product quality enhancement. In order to clearly distinguish product recalls from product enhancements, the FDA published at the end of February a draft guideline (entitled "Distinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements"), which is designed for both the industry and the FDA itself. The draft - composed of 15 pages - has been primarily created in a question-and-answer style. Yet, the draft begins with a chapter of definitions (What is a recall? What is product enhancement? Etc...). A decision making flow chart - whether a product recall should be made or not - finally completes the questions and answers. The draft can be commented within 90 days of publication.
Conclusion: The new draft guideline "Distinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements" is a useful document to better understand the sensitive issue of medical device recalls.
Related GMP News
10.09.2025Artificial Intelligence in Medical Devices - the Perspective of Notified Bodies
10.09.2025The small but significant Difference between EN 13485 and EN ISO 13485
10.09.2025Audits of Medical Device Importers
21.01.2025FDA Warning Letter Statistics on Medical Devices in the past Fiscal Year
21.01.2025Artificial Intelligence in Medical Devices - Notified Bodies' Point of View
21.01.2025New FDA Guidance on Risk Analyses for Drugs, Biologics and Combination Products